Fresh health fears sparked as Donald Trump's 'hidden leg brace' spotted
New images of Donald Trump have sparked fresh speculation about the president's health as he's accused of wearing a hidden leg brace.
After returning to the White House from Camp David, Maryland, on Monday, Trump headed out to the Rose Garden to look over a construction project currently taking place. The president was photographed speaking with construction workers while standing on a wooden board that had been placed on the lawn.
Internet sleuths were quick to zoom in on the image and point out an unusual shape in his trouser leg as theories quickly spread online. "What's going on here?," one X account wrote as it shared four images of Trump's legs. There is another alarming theory for the mystery bulge on Trump's leg which is causing major fears.
If you can't see the picture below, click here
"Leg braces," one user responded. "Maybe to prevent the leaning," the original poster wrote back. Others agreed.
One wrote: "Looks like he has medical knee braces on both of his legs!!!!!" A second commented: "Looks like he has some kind of brace on & his pants legs gathered around it."
A third added: "He's wearing AFOs. Ankle Foot Orthotics. For foot drop. I wear one because of nerve damage to my spine. That's exactly what my pant leg looks like."
Others speculated that he may have even been waring a catheter. "Foley catheter. Urinary incontinence is a symptom of late stage Prefrontal Temporal Dementia," one wrote.
"He is wearing an urine bag or something,you can see the catheter under his pants," another claimed. But others dismissed the theories, claiming there was a much simpler explanation.
"Wrinkles in his pants? Drrrr," one said. Another agreed, writing: "Wrinkles in the suite? Who tf cares?" The president was given a clean bill of health by his doctor, Captain Sean Barbabella, earlier this year.
Some people also believe the strange, snaky lump just below his left knee could be a catheter.
The White House physician said he was in 'excellent cognitive and physical health' in April. As part of a nearly five-hour medical examination at the Walter Reed hospital in Bethesda, Maryland, Trump received several blood tests, a cardiac examination and ultrasounds, his doctor said.
He also underwent neurological tests on his mental status, nerves, motor and sensory function and reflexes and completed the Montreal Cognitive Assessment (MoCA). He scored 30 out of 30, Dr Barbabella said.
"I got the highest mark," Trump boasted. He said the exam showed a "good heart, a good soul, very good soul."
Despite this, a political strategist for the Republican party has warned that Trump may not last four years as he claims the controversial leader could be showing signs of cognitive decline. Rick Wilson, who also co-founded the Lincoln Project, has warned that some experts are suggesting Trump may be in the early stages of dementia.
Speaking to Times Radio, Rick claimed that Trump's decline was noticeable not just when compared to 2015, but to 2024 and his run for a second presidential term.
He said: 'He is incoherent. His inability to articulate any thought or position without constant asides, constant lapses, the verbal aphasias he is experiencing at various points.
'As a very close observer of Trump since 2015, I can tell you the man you're watching today is not the Trump of 2015, nor is he the Trump of 2020, he's not even the Trump of 2024."
He continued: 'There is a decline in Trump's ability to communicate, there is a decline in Trump's ability to articulate his thoughts. This is not uncommon when people get older.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
4 days ago
- RTÉ News
Lilly to hike UK price of Mounjaro weight-loss drug by 170%
Eli Lilly said will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, amid a White House push to get drugmakers to raise medicine prices in Europe to allow for pricecuts in the United States. The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from price for a month's supply of the highest dose of the medicine will increase from £122 to £330, Lilly said. The higher price will affect those who pay for Mounjaro privately, but will not affect those prescribed the medicine through the British public healthcare system, which has a separate deal, a Lilly spokesperson said. The US drugmaker said that when it launched Mounjaro in Britain it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through Britain's National Health Service (NHS). "We are now aligning the list price more consistently,"Lilly said. The move reflects how the pharmaceutical industry is navigating policy changes in the United States, by far its most lucrative market, where President Donald Trump is pushing for lower domestic prices and encouraging price hikes overseas. Last week Eli Lilly CEO David Ricks told an investor call that parity between US and European drug pricing was desirable in the long run, though he warned that European governments "are not signing up to pay more for drugs". The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Trump says he wants to narrow this gap to stop Americans from being "ripped off." It was reported last week that the Trump administration has been talking to drugmakers about ways to level the playing field for medicine prices. A list price is set by the drug manufacturer before any rebates or discounts. Lilly said it was working with private UK healthcare providers, such as online pharmacies, who can set their own prices, to ensure continued access to the medicines. Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023.
Irish Times
6 days ago
- Irish Times
‘Don't underestimate this guy': Who is Gareth Sheridan, the pharma millionaire running for president?
Gareth Sheridan is, in one respect, the face of the impact of Donald Trump's tariffs. The share price of Nutriband, the business he cofounded in 2012, has dropped by almost 10 per cent in the past month, affected by the US tariffs uncertainty. For the year to date, it's still up by 57 per cent and the pharma company has a market value of $80 million (€69 million) – it was valued at $100 million in January. Nutriband has yet to generate any revenue and is awaiting US Food and Drug Administration (FDA) approval for its technology, which is designed to prevent abuse of patch medications. Sheridan has talked about the technology in the second quarter of next year, if not before, subject to FDA approval. READ MORE Sheridan wants to be the next president of Ireland, having announced his plans to seek the nomination through local councils. He needs the support of four local authorities to get on the ballot paper. The 35-year-old, from Terenure, south Dublin, lacks the support from the Oireachtas of Mairéad McGuinness or Catherine Connolly , or the name recognition of Michael Flatley or Conor McGregor , both of whom have indicated interest in running for the office. As an unaffiliated unknown, the road to Áras an Uachtaráin looks to be a long one for the entrepreneur. The challenge gets tougher when you consider that Seán Gallagher's second-place finish in 2011, with 28.5 per cent of first preference votes, is the best performance by any candidate to go the council route in the election. Gallagher, as it happens, is executive chairman of Nutriband. [ Pharma businessman Gareth Sheridan enters presidential race as Independents compete for nominations ] The Technological University Dublin (TU Dublin) graduate's lack of name recognition or party support means that even getting on the ballot is a daunting prospect. It's one that he has likely prepared for, says Dr Siobhán Killion, head of management at TU Dublin's school of management, people, and organisations. 'Don't underestimate this guy,' Killion says. 'I mentioned his name to a few people on Sunday. They didn't have a clue who he was. His biggest obstacle is to become known, but he's no fool and he'll rise to the challenge. There'll be very few people in Ireland come November that won't have heard of him. 'He's such a busy guy, but it doesn't surprise me. He seems to be the king of time management. He's very much on top of his game.' Sheridan did his undergraduate degree at TU Dublin while in the process of establishing Nutriband. 'It was at the expense of my grades,' he told The Irish Times in February. 'My dad wears a patch for heart medication. I figured patch technology could be expanded. As I wrote my thesis, it felt more like a business plan,' he says. Killion got to know him at TU Dublin. 'He knows how to juggle commitments. His ability to keep all the balls in the air successfully is something he's got in spades,' she says. 'He was the guy that didn't attend classes because he was working on his business idea. That's okay because not everybody's academic journey is the same. He did what he needed to do to get where he needed to be.' Killion has stayed in contact with Sheridan since, inviting him back to speak to students in TU Dublin. 'Gareth, being an alum of TU Dublin, has freely given his time to encourage entrepreneurship among our students. Any time I've reached out to him, he's come back without hesitation to help,' she says. 'He's a great mentor to students. These are undergrads, your typical 20-year-olds, and he's in there with them advising and encouraging them.' In February, Sheridan said his goal was to 'put manners' on the largest pharmaceutical companies in the US. Nutriband has developed a system to change the way patches of painkillers such as fentanyl and other opiates work. The aim is to reduce abuse and prevent risk of accidental exposure. 'They're competitors. We're coming in aggressively and to put manners on an industry that has ignored a major issue for a long time. I am baffled that the industry has let prescription rates drop so much without attempting a fix,' he said at the time. The route to getting the business off the ground and on to the Nasdaq stock exchange in New York involved Sheridan working in food delivery and other gig economy roles to keep the company functioning while awaiting approval to get listed. The company is based in Orlando, Florida, and he has resided in Salt Lake City, Utah, his wife's home city, but is in the process of moving back to Dublin. Sheridan documented his journey in his autobiography, From No to Nasdaq, which came out earlier this year. The bullish approach came as no surprise to Aonghus Shortt, cofounder of FoodMarble. Shortt's company is working on gut health, having raised €8 million to date. He met Sheridan in 2022. 'He approached me via LinkedIn. He was listed on Nasdaq [in 2021] and for a company that size it was somewhat unprecedented among Irish start-ups. I'm sure one million people told him it was a horrible idea, but he made it work,' Shortt says. 'When we met up, he was encouraging me to consider listing. We didn't, but I was impressed he did. He's a very confident guy and an independent thinker. I found him quite impressive.' Sheridan is stepping back from his role with Nutriband, where he owns 18 per cent of the business, during his presidential run. Were he to win, he would have to remain detached from the company. His co-founder, Serguei Melnik, is taking charge in his absence. 'He [Sheridan] seems nice and transparent, but what he did [with Nutriband] was audacious. It's weathered some storms,' Shortt says. 'It's another audacious move. It's not a very big company or stock, so it's not like all eyes in the US will be on what he does, but you can imagine some shareholders might be wondering why he's doing this.' Sheridan is one of 24 finalists chosen to compete for the title of EY Entrepreneur of the Year awards. He has been chosen along with seven others in the established category. The winner of that category would then vie with the two other category winners (emerging and international) for the overall title. One of Nutriband's shareholders is Jim Breen. The PulseLearning founder met Sheridan on an EY Entrepreneur of the Year CEO retreat to Japan earlier this year. Breen was a nominee in 2007. 'There were around 140 of us in Japan for a week. It was my first time meeting him. He's got a special kind of mentality that mixes humility with confidence. He's a learner, but he's also experienced. The part that impressed me most was that he's had knock-backs, but has resilience about him,' Breen says. Having invested in the company based on that meeting in Japan, Breen acknowledges that it is less than optimal to have Sheridan stepping away from the business for a run at the Áras. 'It's not ideal from an investor perspective. However, he's got the thing well thought through. A Nasdaq-listed company has a team of people in place, it doesn't depend on just one person,' Breen says. 'With some things in business and life, you just work them out.' A spokesman for Sheridan told The Irish Times that he 'holds dual citizenship' for the US and Ireland. A statement said: 'As regards holding or contesting for the office of president of Ireland there are clear precedents regarding Ireland-USA dual citizenship holders. 'In 1959, Éamon de Valera , a USA citizen (by birth), was nominated and elected president of Ireland.' On Newstalk on Monday Sheridan denied he had renounced allegiance to Ireland as the oath on taking up US citizenship requires. Queried by The Irish Times, his spokesman acknowledged that 'as tens of thousands of Irish people before him faced with the choice of being undocumented or 'legal' in the US, Gareth Sheridan was 'naturalised', taking dual citizenship, he pledged allegiance to the USA. That to him meant allegiance while resident in the US, albeit involving renouncing his allegiance to any other 'power'. 'However, he and all Irish people of dual citizenship with the USA continue to be Irish citizens. While residing in the US for seven years he retained and used his Irish passport. He and his family are now legal residents of Ireland.' Perhaps there is an echo of de Valera's 'empty formula' taking the oath of allegiance on entering the Dáil in 1926. But otherwise, following in de Valera's footsteps appears a long shot. He first needs to get himself on the ballot paper, which will be challenging in itself. But Sheridan has never lacked ambition in business and he will seek to apply his skills as an entrepreneur to the political arena. Additional reporting by Pat Leahy
Irish Independent
10-08-2025
- Irish Independent
Luke O'Neill: RFK Jr's cuts to US vaccine programmes signal a return to the dark ages
Citing not a shred of scientific evidence, Trump's health secretary Robert F Kennedy Jr has cut federal support for new vaccines that could have saved millions of lives Why is Robert F Kennedy Jr ignoring science? The US Department of Health and Human Services, which he runs, has cancelled 22 federal contracts for new vaccines based on the RNA technology that freed us from the Covid-19 pandemic. The move has caused consternation among doctors in the US and Europe. Dr Jennifer Nuzzo, head of Brown University's Pandemic Centre, said it was 'profoundly disappointing'. Dr Michael Osterholm, director of the University of Minnesota's Centre for Infectious Disease Research and Policy, called it 'the most dangerous public health judgment that I've seen in my 50 years'.
